Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Total Current Liabilities (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Total Current Liabilities for 3 consecutive years, with $13.1 million as the latest value for Q4 2025.

  • For Q4 2025, Total Current Liabilities rose 6.81% year-over-year to $13.1 million; the TTM value through Dec 2025 reached $13.1 million, up 6.81%, while the annual FY2025 figure was $13.1 million, 6.81% up from the prior year.
  • Total Current Liabilities hit $13.1 million in Q4 2025 for Artiva Biotherapeutics, up from $11.1 million in the prior quarter.
  • Across five years, Total Current Liabilities topped out at $13.3 million in Q3 2024 and bottomed at $10.8 million in Q2 2025.
  • Average Total Current Liabilities over 3 years is $12.0 million, with a median of $12.2 million recorded in 2023.
  • On a YoY basis, Total Current Liabilities climbed as much as 6.81% in 2025 and fell as far as 16.35% in 2025.
  • Artiva Biotherapeutics' Total Current Liabilities stood at $12.2 million in 2023, then grew by 0.21% to $12.3 million in 2024, then rose by 6.81% to $13.1 million in 2025.
  • According to Business Quant data, Total Current Liabilities over the past three periods came in at $13.1 million, $11.1 million, and $10.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.